Featured Research

from universities, journals, and other organizations

Hopes Raised For Effectiveness Of Multiple Sclerosis Drug

Date:
March 29, 2006
Source:
University of Cincinnati
Summary:
Understanding mechanism of action of drug show why it helps MS patients and how it might also help manage other autoimmune diseases.

Discovery of the mechanism of a drug being tested for the treatment of multiple sclerosis (MS) has revealed that it's not only more effective than first thought, but might also help in the management of other autoimmune diseases, organ transplant rejection and even cancer.

A research team led by the University of Cincinnati's Bibiana Bielekova, MD, report new insights into the role of the MS drug daclizumab (Zenapax) in the March 27 online version of the Proceedings of the National Academy of Sciences. The article will appear in print April 11.

The exact cause of MS is unknown, but one theory is that it may it be triggered by exposure to a viral infection or environmental influences. The disease takes different courses in different people and can go into remission for many years, recurring occasionally or progressing quickly into degeneration of all motor functions that control muscles, strength, vision and balance. The very progressive form of the disease can end in death.

Scientists have long thought that in MS the specific white cells (T-cells) that fight off infection actually turn on the body they are supposed to protect, attacking the myelin sheath that protects the nerves.

"Without the insulating cover, the nerve axons short-circuit, much like a damaged electric cord might," says Dr. Bielekova, director of UC's Waddell Center for Multiple Sclerosis. "Also, many nerve cells (neurons) do not survive without myelin sheath."

It was also believed that since activated T-cells need a growth factor called interleukin 2 for their function, drugs that can block the interaction of interleukin-2 and T-cells could be used to control MS.

Daclizumab is being tested against MS because it has already proved useful in preventing rejection of transplanted organs, "and we thought it works by inhibiting T-cell activation," Bielekova says.

Earlier research by Dr. Bielekova and her group showed that daclizumab benefits MS patients, especially those who have highly inflammatory MS. This latest study, sponsored by the National Institutes of Health (NIH), involved 22 MS patients.

"We monitored T-cell function in patients who were injected with the drug, expecting to see that the drug inhibited T-cell function," says Dr. Bielekova.

"We didn't see that at all. To our surprise the T-cells were functioning normally."

But something unexpected was happening -- the numbers of T-cells circulating in the blood of patients taking daclizumab were declining by about 10 percent. Simultaneously, the number of immune cells known as "regulatory natural killer cells," which are very rare in normal human blood, increased.

Regulatory natural killer cells are known to proliferate in special conditions, such as pregnancy or bone marrow transplantation.

"Not only did the number of regulatory natural killer cells increase in patients treated with daclizumab," says Dr. Bielekova, "but that expansion correlated with the treatment outcome--the more these cells expanded, the better the MS patients did during the trial. And the longer the patients were on the therapy, the more regulatory natural killer cells they had and the better they responded to treatment."

"The best news is that natural killer cells are actually very efficient immune cells that fight viruses or cancers," says Dr. Bielekova, "so it appears that daclizumab doesn't damage the immune system. It only shifts the emphasis of the immune reaction from T-cells to natural killer cells. However, larger studies need to be performed to evaluate the safety of long-term daclizumab therapy."

The current results, however, suggest that daclizumab might also help in the management of autoimmune diseases, organ transplant rejection and perhaps even cancer, she says.

Having found one drug pathway that appears to be important for the treatment of MS, Dr. Bielekova says, "The hope is that we can learn how to enhance this pathway by drugs that can be taken orally, rather than injected." As a result of these findings by Dr. Bielekova's research team, daclizumab is now being tested as a possible MS treatment in a phase-2 trial across the United States, including UC, and Europe.

Dr. Bielekova is a member of the Neuroscience Institute, a collaborative of nine academic departments at UC College of Medicine, University Hospital and independent physician practice groups. The institute is dedicated to patient care, research, education and the development of new medical technologies.

The study was conducted at the Neuroimmunology Branch (NIB) of the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). Coauthors include Marta Catalfamo, PhD, of the National Cancer Institute (NCI); Susan Reichert-Scrivner, MS, Amy Packer and Magdalena Cerna, NINDS; Thomas Waldmann, MD, NCI; Henry McFarland, MD, NINDS, Pierre Henkart, PhD, NCI; and Roland Martin, MD, NINDS.

The NIH applied for two patents related to this discovery that have been bought by drug companies. Dr. Bielekova and three coauthors. Dr. Waldmann, Dr. McFarland and Dr. Martin, are each receiving patent royalty payments from the NIH.



Story Source:

The above story is based on materials provided by University of Cincinnati. Note: Materials may be edited for content and length.


Cite This Page:

University of Cincinnati. "Hopes Raised For Effectiveness Of Multiple Sclerosis Drug." ScienceDaily. ScienceDaily, 29 March 2006. <www.sciencedaily.com/releases/2006/03/060328183227.htm>.
University of Cincinnati. (2006, March 29). Hopes Raised For Effectiveness Of Multiple Sclerosis Drug. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2006/03/060328183227.htm
University of Cincinnati. "Hopes Raised For Effectiveness Of Multiple Sclerosis Drug." ScienceDaily. www.sciencedaily.com/releases/2006/03/060328183227.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Microneedle Patch Promises Painless Pricks

Microneedle Patch Promises Painless Pricks

Reuters - Innovations Video Online (Oct. 18, 2014) Researchers at The National University of Singapore have invented a new microneedle patch that could offer a faster and less painful delivery of drugs such as insulin and painkillers. Video provided by Reuters
Powered by NewsLook.com
Raw: Nurse Nina Pham Arrives in Maryland

Raw: Nurse Nina Pham Arrives in Maryland

AP (Oct. 17, 2014) The first nurse to be diagnosed with Ebola at a Dallas hospital walked down the stairs of an executive jet into an ambulance at an airport in Frederick, Maryland, on Thursday. Pham will be treated at the National Institutes of Health. (Oct. 16) Video provided by AP
Powered by NewsLook.com
Raw: Cruise Ship Returns to US Over Ebola Fears

Raw: Cruise Ship Returns to US Over Ebola Fears

AP (Oct. 17, 2014) A Caribbean cruise ship carrying a Dallas health care worker who is being monitored for signs of the Ebola virus is heading back to Texas, US, after being refused permission to dock in Cozumel, Mexico. (Oct. 17) Video provided by AP
Powered by NewsLook.com
Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

AFP (Oct. 17, 2014) All four suspected Ebola cases admitted to hospitals in Spain on Thursday have tested negative for the deadly virus in a first round of tests, the government said Friday. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins